Aaron Royston, venBio

In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

Apart from dis­rupt­ing bio­phar­ma R&D and reg­u­la­to­ry time­lines, the coro­n­avirus pan­dem­ic has in­evitably rav­aged fi­nan­cial mar­kets and erod­ed in­vestor risk ap­petite. In­vest­ing in the time of coro­n­avirus feels reck­less, but if biotech ven­ture funds are any in­di­ca­tion, the time is ripe.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.